We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Criteria Established for Western Blot Diagnosis of Lyme Disease

By LabMedica International staff writers
Posted on 20 Sep 2011
Print article
The laboratory diagnosis of Lyme borreliosis (LB) has been dependent mainly on serology with the Western blot test used for confirmation.

To ensure the best use of the Western blot in a routine diagnostic laboratory it is essential that the entire interpretation process remains as simple as possible as a consensus for the interpretation of Western blots to detect Borrelia burgdorferi infection in Europe has been difficult to obtain.

Scientists at the UK National Lyme Borreliosis Testing Service Laboratory, at Raigmore Hospital (Inverness, Scotland) endeavored to interpret what bands are classed as specific, the number of bands needed for a positive result, the role of band intensity combined with clinical information. In 2008, 3,688 patients (4,223 serum samples) were tested by enzyme immunoassay (EIA), with 832 patients tested by confirmatory in-house immunoglobulin IgG Western blot. For a Western blot-positive result, these criteria required at least four bands in total, including the 41 kDa band and a further two specific bands with strong intensity. They found that 272 patients were Western blot-positive, 170 were weak positive, 156 were equivocal, and 234 were negative.

All sera were screened by commercial B. burgdorferi IgM/IgG EIA utilizing B. burgdorferi (B31 strain) antigen produced by Zeus Scientific, (Branchburg, NJ, USA) and the accurate identification of band molecular weight was routinely determined using polyclonal sera obtained from Abcam (Cambridge, UK) and well-categorized Western blot-positive sera. A new interpretation criteria and a testing algorithm were then developed. The revised criteria changed the results in 109/3,688 (3%) patients and produced significantly more Western blot-positive and weak-positive patients than with the current criteria. In total, 76 patients who were negative or equivocal became positive, which may have led to a change in their management. Conversely, 33 patients who were weak-positive became equivocal, but their management may not have been affected.

The most important specific Western blot bands appear to be 20 kDa, 28 kDa, 41 kDa, and 48 kDa, but other maybe as significant. The authors concluded that the revised criteria have simplified blot interpretation and improved the sensitivity and robustness of their Western blot method. Using a protocol tailored to patients that incorporates clinical characteristics means that the entire process will be easier and will aid the management of patients. The study was accepted for publication on August 27, 2011, in the British Journal of Biomedical Science.

Related Links:
UK National Lyme Borreliosis Testing Service
Zeus Scientific
Abcam

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.